Research Papers What Patients Tell Us about Primary Healthcare Evaluation Instruments: Response Form, Bad Questions and Missing Pieces

 Blogger's Note: there is a bias in this report (demographics of participants), however, an interesting read and in particular the integrity of the participants as per one quote below

sample:

Bad questions

When asked about questions they did not like, respondents consistently stated they did not like assessing processes occurring in the provider's mind or that they did not directly observe or experience. Almost all questionnaires contained such questions.....

Obstetrics/Gynecology articles: The New England Journal of Medicine (2 articles)

SpecialtyObstetrics/Gynecology

original article

Bevacizumab in the Treatment of Ovarian Cancer

December 29, 2011 | R.A. Burger
and Others

Incorporating bevacizumab in a chemotherapy regimen (7.5 mg/kg every 3 weeks for five or six cycles) and then continuing bevacizumab alone for a total of 12 months of treatment extended progression-free survival in advanced and high-risk earlystage ovarian cancer.

Bevacizumab in Ovarian Cancer Treatment

December 29, 2011 | T.J. Perren
and Others

The addition of bevacizumab to chemotherapy (15 mg/kg for six cycles) followed by extended therapy with bevacizumab every 3 weeks for a total of 15 months of treatment improved progression-free survival by 4 months in incompletely resected stage III or IV ovarian cancer.

Recurrent Somatic DICER1 Mutations in Nonepithelial Ovarian Cancers — NEJM

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer — NEJM

Blogger's Note: see also the section 'Media in This Article'

Low-Molecular-Weight Heparin and Mortality in Acutely Ill Medical Patients — NEJM (Lovenox (enoxaparin)

Essential gene profiles in breast, pancreas and ovarian cancer cells

Doctors Are Cautious, Patients Enthusiastic About Sharing Medical Notes - Beth Israel Deaconess Medical Center

Roche's Avastin - Trials And Triumphs (overview/history)